June 12 – 17, 2022
The current state-of-the-art for the production of glycoconjugate vaccines is a lengthy and complex series of process steps. An exciting alternative is Protein Glycan Coupling Technology (PGCT), where glycoconjugates are produced in vivo 1,2. This offers a significant reduction in the time and cost burden of glycoconjugate production, making this technology much more feasible for providing vaccines in developing countries. Current research seeks to apply this technology for pneumococcal vaccines 2, however much process optimisation must be done before this is achievable. This work seeks to provide an automated screening platform at the microscale, enabling the rapid screening of different process variables at considerably smaller volumes
Please click Download on the upper right corner to see the full abstract.
Jasmin J. Samaras and Martina Micheletti, "Development of an automated microscale platform for conjugate vaccine production in E. coli" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/19